Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations identifier:
NCT04042831 (


Study Contact Information:

For additional information, please contact: Principal Investigator: Daniel H Ahn at Mayo Clinic in Arizona  

About the Study

This study will look at how well the PARP inhibitor olaparib works in treating women or men who have been diagnosed with biliary tract (bile duct) cancer that has metastasized to other places in the body and who also have DNA repair gene mutations that give them a higher risk of certain cancers.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Type of Study

This is an open-label, single-group study. 

All participants will receive the same treatment. 

What the Study Entails

Participants will receive olaparib orally twice per day on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.

Study Sites

This Study is Open To:

Men or women age 18 years or older can participate if they:  

This Study is Not Open To:

Patients will be excluded if they have:  


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.